Investigating the ileal microbiota biomechanical characteristics of patients with metabolic associated fatty liver disease (MAFLD)
Abstract
Objective: To investigate the biomechanical characteristics of ileal microbiota in patients with metabolic associated fatty liver disease (MAFLD). Methods: 72 patients with MAFLD were recruited in our hospital between January 2024 and November 2024. They were divided into mild fatty liver (MF group, n = 36) and moderate to severe fatty liver (SF group, n = 36) based on CAP values, and a healthy control group (H, n = 36) was included. The ileal microbiota was sampled using endoscopy with newly designed accessories, followed by 16S rDNA sequencing to analyze the biomechanical properties of the microbial community. Results: Compared with the control group, Alpha diversity of ileal flora in MAFLD group elevated, a gradual decrease in the percentage of Turicibacter, a decrease in the abundance of Lactobacillus and Veillonella, but an increase in the abundance of Prevotella, Leptotrichia, Porphyromonas. Conclusion: The biomechanical diversity and abundance of ileal microbiota in MAFLD patients change, which is related to the severity of the disease. The reduction of Turicibacter and the migration of oral colonizing bacteria are characteristic features of the ileal microbiota in MAFLD patients, potentially influencing the biomechanical interactions within the gut environment.
References
1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5): 1797-1835. doi: 10.1097/hep.0000000000000323
2. Sun DQ, Targher G, Byrne CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surgery and Nutrition. 2023; 12(3): 386-403. doi: 10.21037/hbsn-22-421
3. Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022; 42(6). doi: 10.1161/atv.0000000000000153
4. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2022; 7(9): 851-861. doi: 10.1016/S2468-1253(22)00165-0
5. Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. International Journal of Molecular Sciences. 2020; 21(15): 5214. doi: 10.3390/ijms21155214
6. Collins SL, Stine JG, Bisanz JE, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nature Reviews Microbiology. 2022; 21(4): 236-247. doi: 10.1038/s41579-022-00805-x
7. Sun XW, Li HR, Jin XL, et al. Structural and Functional Differences in Small Intestinal and Fecal Microbiota: 16S rRNA Gene Investigation in Rats. Microorganisms. 2024; 12(9): 1764. doi: 10.3390/microorganisms12091764
8. Tang Q, Jin G, Wang G, et al. Current Sampling Methods for Gut Microbiota: A Call for More Precise Devices. Frontiers in Cellular and Infection Microbiology. 2020; 10. doi: 10.3389/fcimb.2020.00151
9. Keam SJ. Resmetirom: First Approval. Drugs. 2024; 84(6): 729-735. doi: 10.1007/s40265-024-02045-0
10. Cusi K. A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Liver International. 2020; 40(S1): 82-88. doi: 10.1111/liv.14350
11. Gottlieb A, Canbay A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells. 2019; 8(11): 1358. doi: 10.3390/cells8111358
12. Wei J, Luo J, Yang F, et al. Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine. Gut Microbes. 2024; 16(1). doi: 10.1080/19490976.2024.2351620
13. Kemis JH, Linke V, Barrett KL, et al. Genetic determinants of gut microbiota composition and bile acid profiles in mice. PLOS Genetics. 2019; 15(8): e1008073. doi: 10.1371/journal.pgen.1008073
14. Chen Y, Xu C, Huang R, et al. Butyrate from pectin fermentation inhibits intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E-deficient mice. The Journal of Nutritional Biochemistry. 2018; 56: 175-182. doi: 10.1016/j.jnutbio.2018.02.011
15. Zhong Y, Nyman M, Fåk F. Modulation of gut microbiota in rats fed high‐fat diets by processing whole‐grain barley to barley malt. Molecular Nutrition & Food Research. 2015; 59(10): 2066-2076. doi: 10.1002/mnfr.201500187
16. Lynch JB, Gonzalez EL, Choy K, et al. Gut microbiota Turicibacter strains differentially modify bile acids and host lipids. Nature Communications. 2023; 14(1). doi: 10.1038/s41467-023-39403-7
17. Lau HCH, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. eBioMedicine. 2024; 100: 104952. doi: 10.1016/j.ebiom.2023.104952
18. Shanahan ER, Zhong L, Talley NJ, et al. Characterisation of the gastrointestinal mucosa‐associated microbiota: a novel technique to prevent cross‐contamination during endoscopic procedures. Alimentary Pharmacology & Therapeutics. 2016; 43(11): 1186-1196. doi: 10.1111/apt.13622
19. Mottawea W, Butcher J, Li J, et al. The mucosal–luminal interface: an ideal sample to study the mucosa-associated microbiota and the intestinal microbial biogeography. Pediatric Research. 2019; 85(6): 895-903. doi: 10.1038/s41390-019-0326-7
20. Koziolek M, Grimm M, Becker D, et al. Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap® System. Journal of Pharmaceutical Sciences. 2015; 104(9): 2855-2863. doi: 10.1002/jps.24274
21. Cui J, Zheng X, Hou W, et al. The Study of a Remote-Controlled Gastrointestinal Drug Delivery and Sampling System. Telemedicine and e-Health. 2008; 14(7): 715-719. doi: 10.1089/tmj.2007.0118
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
